Alzheimer disease (AD), the most common senile dementia, is characterized by amyloid plaques, vascular amyloid, neurofibrillary tangles, and progressive neurodegeneration. Amyloid is mainly composed by amyloid- (A) peptides, which are derive from processing of the -amyloid precursor protein (APP), better named amyloid- precursor protein (APP), by secretases. The APP intracellular domain (AID), which is released together with A, has signaling function, since it modulates apoptosis and transcription. Despite its biological and pathological importance, the mechanisms regulating APP processing are poorly understood. As cleavage of other ␥-secretase substrates is regulated by membrane bound proteins, we have postulated the existence of integral membrane proteins that bind APP and regulate its processing. Here, we show that BRI2, a type II membrane protein, interacts with APP. Interestingly, 17 amino acids corresponding to the NH 2 -terminal portion of A are necessary for this interaction. Moreover, BRI2 expression regulates APP processing resulting in reduced A and AID levels. Altogether, these findings characterize the BRI2-APP interaction as a regulatory mechanism of APP processing that inhibits A production. Notably, BRI2 mutations cause familial British (FBD) and Danish dementias (FDD) that are clinically and pathologically similar to AD. Finding that BRI2 pathogenic mutations alter the regulatory function of BRI2 on APP processing would define dysregulation of APP cleavage as a pathogenic mechanism common to AD, FDD, and FBD. APP1 is an ubiquitous type I transmembrane protein (1, 2) that undergoes a series of endoproteolytic events (3-5). APP is first cleaved at the plasma membrane or in intracellular organelles by -secretase (6). While the ectodomain is released extracellularly (sAPP) or into the lumen of intracellular compartments, the COOH-terminal fragment of 99 amino acids (C99) remains membrane bound. In a second, intramembranous proteolytic event, C99 is cleaved, with somewhat lax site specificity, by the ␥-secretase. Two peptides are released in a 1:1 stoichiometric ratio: the amyloidogenic A peptide, consisting of 2 major species of 40 and 42 amino acids (A40 and A42, respectively), and an intracellular product named AID or AICD, which is very short-lived and has been identified only recently (7-9). In an alternative, nonamyloidogenic proteolytic pathway, APP is first processed by ␣-secretase in the A sequence leading to the production of the sAPP␣ ectodomain and the membrane-bound COOH-terminal fragment of 83 amino acids (C83). C83 is also cleaved by the ␥-secretase into the P3 and AID peptides. While A is implicated in the pathogenesis of Alzheimer disease, AID mediates most of the APP signaling functions. A pathogenic role for APP processing in AD has been ascertained by the finding that mutations in presenilins (10 -13), key components of the ␥-secretase, and APP (14) cause autosomal dominant familial forms of AD. Thus, because of its biological and pathological import...
Our study identifies Twinkle mutations as a cause of Perrault syndrome accompanied by neurologic features and expands the phenotypic spectrum of recessive disease caused by mutations in Twinkle. The phenotypic heterogeneity of conditions caused by Twinkle mutations and the genetic heterogeneity of Perrault syndrome call for genomic definition of these disorders.
BackgroundSpinocerebellar ataxia (SCA) is a genetically heterogeneous disease. To date, 36 dominantly inherited loci have been reported, and 31 causative genes have been identified.ResultsIn this study, we analyzed a Japanese family with autosomal dominant SCA using linkage analysis and exome sequencing, and identified CACNA1G, which encodes the calcium channel CaV3.1, as a new causative gene. The same mutation was also found in another family with SCA. Although most patients exhibited the pure form of cerebellar ataxia, two patients showed prominent resting tremor in addition to ataxia. CaV3.1 is classified as a low-threshold voltage-dependent calcium channel (T-type) and is expressed abundantly in the central nervous system, including the cerebellum. The mutation p.Arg1715His, identified in this study, was found to be located at S4 of repeat IV, the voltage sensor of the CaV3.1. Electrophysiological analyses revealed that the membrane potential dependency of the mutant CaV3.1 transfected into HEK293T cells shifted toward a positive potential. We established induced pluripotent stem cells (iPSCs) from fibroblasts of the patient, and to our knowledge, this is the first report of successful differentiation from the patient-derived iPSCs into Purkinje cells. There was no significant difference in the differentiation status between control- and patient-derived iPSCs.ConclusionsTo date, several channel genes have been reported as causative genes for SCA. Our findings provide important insights into the pathogenesis of SCA as a channelopathy.Electronic supplementary materialThe online version of this article (doi:10.1186/s13041-015-0180-4) contains supplementary material, which is available to authorized users.
Proteolytic processing of amyloid  protein precursor (APP) generates peptides that regulate normal cell signaling and are implicated in Alzheimer's disease pathogenesis. APP processing also occurs in nerve processes where APP is transported from the cell body by kinesin-I, a microtubule motor composed of two kinesin heavy chain and two kinesin light chain (Klc) subunits. APP transport is supposedly mediated by the direct APP-Klc1 interaction. Here we demonstrate that the APP-Klc1 interaction is not direct but is mediated by JNK-interacting protein 1 (JIP1). The phosphotyrosine binding domain of JIP1 binds the cytoplasmic tail of APP, whereas the JIP1 C-terminal region interacts with the tetratrico-peptide repeats of Klc1. We also show that JIP1 does not bridge the APP gene family member APP-like protein 2, APLP2, to Klc1. These results support a model where JIP1 mediates the interaction of APP to the motor protein kinesin-I and that this JIP1 function is unique for APP relative to its family member APLP2. Our data suggest that kinesin-I-dependent neuronal APP transport, which controls APP processing, may be regulated by JIP1.Alzheimer's disease is characterized by the deposition of A peptides, which are cleaved off from APP 1 (1, 2). APP is transported along axons via conventional kinesin-I-dependent fast anterograde transport (3, 4), which might be involved in processing of APP (5). It has been proposed that the kinesindependent transport of APP is mediated by the direct binding of APP to the TPR domain of Klc (4).The TPR domain of Klc has been shown to bind JIP proteins (6). The JIP protein family, members of which were initially isolated as scaffolds for kinases of the JNK cascade, consists of three proteins: JIP1 (7), JNK-interacting protein 2 (JIP2) (8), and JSAP1/Sunday Driver/JNK-interacting protein 3 (JIP3) (9 -11). JIP1 has two alternatively spliced forms in mouse, JIP1a, and JIP1b. JIP1b (referred to as JIP1 in this manuscript) and JIP2, which are conserved between human and mouse, contain a C-terminal Src homology region 3 and a PTB domain. JIP1a, which has not been found in humans, lacks a complete PTB domain. JIP3 is structurally unrelated (11). Of interest, JIP1 has also been identified in yeast two-hybrid screenings performed to isolate APP-interacting proteins. The PTB domain of JIP1 binds to the YENPTY motif found in the APP intracellular domain (AICD/AID) (12, 13). The biological relevance of the JIP1-APP interaction is underlined by the evidence that these two proteins interact in mouse brain (13).The direct binding of Klc to AID has been a puzzle to us because Klc has never been cloned as an AID-interacting protein, despite extensive yeast two-hybrid screenings performed in many laboratories, including ours. On the contrary, Klc1 was one of the predominant proteins isolated in yeast two-hybrid screening using the C terminus of JIP1 as bait (data not shown). This apparent paradox can be resolved by postulating that the interaction between Klc and APP is indirect and tha...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.